AR079876A1 - Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma - Google Patents

Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma

Info

Publication number
AR079876A1
AR079876A1 ARP100103608A ARP100103608A AR079876A1 AR 079876 A1 AR079876 A1 AR 079876A1 AR P100103608 A ARP100103608 A AR P100103608A AR P100103608 A ARP100103608 A AR P100103608A AR 079876 A1 AR079876 A1 AR 079876A1
Authority
AR
Argentina
Prior art keywords
sialic acid
gonadotrophine
same
recombinant human
high content
Prior art date
Application number
ARP100103608A
Other languages
English (en)
Spanish (es)
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of AR079876A1 publication Critical patent/AR079876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP100103608A 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma AR079876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
AR079876A1 true AR079876A1 (es) 2012-02-29

Family

ID=41471027

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103608A AR079876A1 (es) 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Country Status (25)

Country Link
US (5) US8975226B2 (enExample)
EP (2) EP2486051B1 (enExample)
JP (6) JP6176924B2 (enExample)
KR (7) KR102213154B1 (enExample)
CN (1) CN107050434B (enExample)
AR (2) AR079876A1 (enExample)
AU (1) AU2010304922B2 (enExample)
BR (1) BR112012007990A2 (enExample)
CA (1) CA2776790A1 (enExample)
DK (1) DK2486051T3 (enExample)
ES (2) ES3036152T3 (enExample)
HR (1) HRP20200941T1 (enExample)
HU (1) HUE050793T2 (enExample)
IL (3) IL218548A (enExample)
IN (1) IN2012DN02073A (enExample)
JO (1) JOP20200039A1 (enExample)
LT (1) LT2486051T (enExample)
MX (1) MX2012003951A (enExample)
PL (1) PL2486051T3 (enExample)
PT (1) PT2486051T (enExample)
RS (1) RS60413B1 (enExample)
RU (2) RU2724528C2 (enExample)
SI (1) SI2486051T1 (enExample)
TW (2) TWI532495B (enExample)
WO (1) WO2011042688A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104919046A (zh) 2012-12-10 2015-09-16 生化学工业株式会社 新重组因子c、其制造方法、及内毒素的测定法
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
WO2019211153A1 (en) * 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
AU2021215893A1 (en) * 2020-02-05 2022-08-25 Novartis Ag CHO cell expressing IL-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法
TWD234354S (zh) * 2023-09-19 2024-10-21 日商富士股份有限公司 (日本) 轉移輔助機
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU747179B2 (en) 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CA2372714A1 (en) * 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
PL205149B1 (pl) * 2000-02-22 2010-03-31 Serono Lab Sposób przygotowania rekombinowanej hCG
HRP20040087A2 (en) 2001-09-12 2004-12-31 Applied Research Systems USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
EA008220B1 (ru) * 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
JP2006522151A (ja) * 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
DK1654353T3 (da) * 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) * 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
JP2009504985A (ja) 2005-08-15 2009-02-05 シーメンス ヴィディーオー オートモーティヴ コーポレイション ディーゼル車排気への炭化水素計量弁
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) * 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
KR101804479B1 (ko) 2017-12-05
JOP20200039A1 (ar) 2022-10-30
ES2798258T3 (es) 2020-12-10
KR20190028823A (ko) 2019-03-19
JP6580104B2 (ja) 2019-09-25
KR101987982B1 (ko) 2019-06-11
AR125991A2 (es) 2023-08-30
TW201632198A (zh) 2016-09-16
KR102213154B1 (ko) 2021-02-05
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
US20200247863A1 (en) 2020-08-06
JP2013506708A (ja) 2013-02-28
AU2010304922A1 (en) 2012-03-29
RU2016118236A3 (enExample) 2019-09-18
PT2486051T (pt) 2020-06-17
US20220340634A1 (en) 2022-10-27
RU2588650C2 (ru) 2016-07-10
RU2016118236A (ru) 2018-10-29
KR20210141771A (ko) 2021-11-23
US10526390B2 (en) 2020-01-07
US8975226B2 (en) 2015-03-10
KR20230012104A (ko) 2023-01-25
CN107050434A (zh) 2017-08-18
MX2012003951A (es) 2012-05-29
JP2018076296A (ja) 2018-05-17
JP2020000246A (ja) 2020-01-09
CN107050434B (zh) 2021-07-27
KR20190067256A (ko) 2019-06-14
IL267556A (en) 2019-08-29
JP2021176867A (ja) 2021-11-11
JP6310440B2 (ja) 2018-04-11
CN102549011A (zh) 2012-07-04
IL250733A0 (en) 2017-04-30
US11292824B2 (en) 2022-04-05
PL2486051T3 (pl) 2020-09-07
LT2486051T (lt) 2020-07-10
KR102489143B1 (ko) 2023-01-13
US9676835B2 (en) 2017-06-13
TW201113030A (en) 2011-04-16
JP2016074680A (ja) 2016-05-12
IN2012DN02073A (enExample) 2015-08-21
EP2486051B1 (en) 2020-03-25
KR20170133531A (ko) 2017-12-05
BR112012007990A2 (pt) 2017-07-25
DK2486051T3 (da) 2020-06-22
US20140249082A1 (en) 2014-09-04
HUE050793T2 (hu) 2021-01-28
KR20210014767A (ko) 2021-02-09
ES3036152T3 (en) 2025-09-15
EP3611185A1 (en) 2020-02-19
JP2023075144A (ja) 2023-05-30
US12234272B2 (en) 2025-02-25
SI2486051T1 (sl) 2020-08-31
AU2010304922B2 (en) 2014-11-06
JP7196244B2 (ja) 2022-12-26
WO2011042688A1 (en) 2011-04-14
JP6176924B2 (ja) 2017-08-09
EP2486051A1 (en) 2012-08-15
RU2724528C2 (ru) 2020-06-23
JP7292153B2 (ja) 2023-06-16
IL218548A (en) 2017-03-30
RU2012112907A (ru) 2013-11-10
US20180030107A1 (en) 2018-02-01
HRP20200941T1 (hr) 2020-09-18
IL218548A0 (en) 2012-05-31
EP3611185B1 (en) 2025-04-30
TWI532495B (zh) 2016-05-11
US20130023476A1 (en) 2013-01-24
IL250733B (en) 2019-07-31
RS60413B1 (sr) 2020-07-31
CA2776790A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
NZ596037A (en) Fgf21 mutants and uses thereof
NZ596849A (en) Serum amyloid p derivatives and their preparation and use
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
AR071479A1 (es) Hormona foliculo estimulante recombinante (rfsh) con union de acido sialico en a2,3 y a2,6
PH12012501895A1 (en) Long-acting formulations of insulins
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
NZ715203A (en) Heparan sulphates
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
BR112013032630A2 (pt) polipeptídeo heterodimerizado
BR112014014913A2 (pt) mutante prongf e método de preparação de uma beta-ngf humana biologicamente ativa
NZ604877A (en) Improved recombinant human follicle-stimulating hormone
BR112012027545A8 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
MY151184A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
NZ609959A (en) Modified factor ix polypeptides and uses thereof
IN2012DN00377A (enExample)
PE20142432A1 (es) Usos terapeuticos de proteinas del factor de crecimiento del fibroblasto 21
CO2017006870A2 (es) Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp
MX2024015741A (es) Alfa-glucosidasa acida humana recombinante
EP4613284A3 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)

Legal Events

Date Code Title Description
FC Refusal